QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications
Qiagen N.V. Common Shares (QGEN)
Last qiagen n.v. common shares earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corporate.qiagen.com/investor-relations
Company Research
Source: GlobeNewswire
Venlo, the Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced key updates to its sample technologies solutions for non-invasive liquid biopsy applications for use in research and clinical applications such as oncology, prenatal care and organ transplantation. “The introduction of these new kits and the updates to our EZ2 Connect platform underline QIAGEN’s commitment to advancing liquid biopsy technologies,” said Nitin Sood, Senior Vice President and Head of the Life Sciences Business Area at QIAGEN. “These enhancements not only expand our portfolio to meet the diverse needs of our customers but also reinforce our leadership in providing high-quality, automated solutions in important fields such as oncology, prenatal care and organ transplant.” Liquid biopsy is a non-invasive method using biofluid samples, such as blood or urine, to detect and monitor disease biomarkers. It is promising for personalized medicine, p
Show less
Read more
Impact Snapshot
Event Time:
QGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QGEN alerts
High impacting Qiagen N.V. Common Shares news events
Weekly update
A roundup of the hottest topics
QGEN
News
- Is it Worth Retaining QIAGEN Stock in Your Portfolio Now? [Yahoo! Finance]Yahoo! Finance
- The past three-year earnings decline for Qiagen (NYSE:QGEN) likely explains shareholders long-term losses [Yahoo! Finance]Yahoo! Finance
- QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio [Yahoo! Finance]Yahoo! Finance
- QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolioBusiness Wire
- QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testingBusiness Wire
QGEN
Earnings
- 2/5/25 - Beat
QGEN
Sec Filings
- 2/7/25 - Form 6-K
- 2/6/25 - Form SCHEDULE
- 1/16/25 - Form 6-K
- QGEN's page on the SEC website